Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination

Launched by BIOASTER · Mar 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new rapid diagnostic test to help identify and monitor onchocerciasis, also known as river blindness, along with other related diseases. The goal is to create a better tool to detect these infections, which can make it easier to track and eliminate them from communities. The study will take place in Cameroon over one year and will involve collecting samples from individuals aged 18 and older who either have one of these infections or do not have any of them at all.

To participate, individuals must be informed about the study and agree to take part by signing a consent form. Eligible participants include those who are mono-infected with the specific parasites involved, or those who are healthy and do not have any of the infections. However, pregnant or breastfeeding women and those who have taken certain treatments in the past six months cannot participate. By the end of the trial, researchers aim to update information on the presence of these diseases in the communities and develop a new test that could help improve control programs for onchocerciasis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects informed of the objectives of the study and who signed a consent form
• • Subjects without filariasis (for control subjects), or
• • Subjects mono-infected with Onchocerca volvulus, or
• • Subjects mono-infected with Loa loa, or
• • Subjects mono-infected with Mansonella perstans or alternatively co-infected with Mansonella perstans and Loa loa
• Exclusion Criteria:
• • Pregnant or breast-feeding women
• • Subjects having taken antihelminthic treatment less than 6 months before the inclusion date